Pulmonary lesions induced by SARS-CoV-2 infection in domestic cats.


Journal

Veterinary pathology
ISSN: 1544-2217
Titre abrégé: Vet Pathol
Pays: United States
ID NLM: 0312020

Informations de publication

Date de publication:
07 2022
Historique:
pubmed: 30 12 2021
medline: 22 6 2022
entrez: 29 12 2021
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019, which ranges from fatal disease in some to mild or subclinical in most affected individuals. Many recovered human patients report persistent respiratory signs; however, lung disease in post-acute infection is poorly understood. Our objective was to describe histologic lung lesions and viral loads following experimental SARS-CoV-2 infection in 11 cats. Microscopic evaluation at 3, 6, 10, or 28 days postinoculation (DPI) identified mild to moderate patchy interstitial pneumonia, bronchiolar epithelial damage, and occlusive histiocytic bronchiolitis. Based on immunohistochemistry, alveolar septal thickening was due to CD204-positive macrophages, fewer B and T lymphocytes, type II pneumocytes, and capillary proliferation with a relative dearth of fibrosis. In blood vessel endothelium, there was reactive hypertrophy or vacuolar degeneration and increased MHC II expression at all time points. Unexpectedly, one cat from the 28 DPI group had severe subacute regionally extensive lymphohistiocytic pneumonia with multifocal consolidation, vasculitis, and alveolar fibrin. Reverse transcriptase-quantitative polymerase chain reaction identified SARS-CoV-2 RNA within the lung at 3 and 6 DPI, and viral RNA was below the limit of detection at 10 and 28 DPI, suggesting that pulmonary lesions persist beyond detection of viral RNA. These findings clarify our comparative understanding of disease induced by SARS-CoV-2 and suggest that cats can serve as an informative model to study post-acute pulmonary sequelae.

Identifiants

pubmed: 34963403
doi: 10.1177/03009858211066840
pmc: PMC9208068
mid: NIHMS1797103
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

696-706

Subventions

Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NIDDK NIH HHS
ID : K12 DK100022
Pays : United States
Organisme : NIH HHS
ID : T32 OD010423
Pays : United States

Références

N Engl J Med. 2020 May 7;382(19):1861-1862
pubmed: 32220206
Emerg Infect Dis. 2021 Feb;27(2):660-663
pubmed: 33496650
EClinicalMedicine. 2020 Jun 25;24:100434
pubmed: 32766543
Science. 2020 May 29;368(6494):1016-1020
pubmed: 32269068
EBioMedicine. 2020 Jul;57:102833
pubmed: 32574956
Mod Pathol. 2020 Jun;33(6):1007-1014
pubmed: 32291399
Genomics. 2020 Sep;112(5):3588-3596
pubmed: 32353474
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Eur Respir Rev. 2020 May 27;29(156):
pubmed: 32461209
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
N Engl J Med. 2020 Aug 6;383(6):592-594
pubmed: 32402157
BMC Mol Biol. 2009 Dec 11;10:106
pubmed: 20003366
Ann Intern Med. 2020 May 5;172(9):629-632
pubmed: 32163542
Vet Pathol. 2014 Mar;51(2):505-26
pubmed: 24569616
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Emerg Microbes Infect. 2020 Dec;9(1):2322-2332
pubmed: 33028154
J Pathol Clin Res. 2019 Apr;5(2):108-114
pubmed: 30697960
Nat Commun. 2020 Nov 27;11(1):6078
pubmed: 33247138
Am J Respir Cell Mol Biol. 2020 Dec;63(6):856-859
pubmed: 32897757
Science. 2020 May 29;368(6494):1012-1015
pubmed: 32303590
Vet Pathol. 2005 May;42(3):321-30
pubmed: 15872378
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Am J Surg Pathol. 2021 May 1;45(5):587-603
pubmed: 33481385
Front Immunol. 2020 Dec 18;11:614256
pubmed: 33391285
Geroscience. 2020 Aug;42(4):1051-1061
pubmed: 32556942
Immunology. 1996 Jan;87(1):127-33
pubmed: 8666424
Proc Natl Acad Sci U S A. 2020 Oct 20;117(42):26382-26388
pubmed: 32994343
Nature. 2020 Sep;585(7824):268-272
pubmed: 32396922
Front Immunol. 2014 Oct 17;5:514
pubmed: 25368618
J Comp Pathol. 2014 Nov;151(4):347-51
pubmed: 25172051

Auteurs

Olivia M Patania (OM)

University of Wisconsin-Madison, Madison, WI, USA.

Shiho Chiba (S)

University of Wisconsin-Madison, Madison, WI, USA.

Peter J Halfmann (PJ)

University of Wisconsin-Madison, Madison, WI, USA.

Masato Hatta (M)

University of Wisconsin-Madison, Madison, WI, USA.

Tadashi Maemura (T)

University of Wisconsin-Madison, Madison, WI, USA.

Kristen A Bernard (KA)

University of Wisconsin-Madison, Madison, WI, USA.

Yoshihiro Kawaoka (Y)

University of Wisconsin-Madison, Madison, WI, USA.
University of Tokyo, Tokyo, Japan.

LaTasha K Crawford (LK)

University of Wisconsin-Madison, Madison, WI, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH